Stem cell therapy has moved from the edges of experimental medicine into a growing number of clinical settings over the past two decades. Patients in Franklin, TN and across the country are asking more specific questions about how these treatments actually work, what they are used for, and how they differ from the conventional care they have received for years. This article offers a clear, research-grounded overview of stem cell therapy, the main types used in clinical practice, the conditions they are applied to, and how this approach compares structurally to standard medical care.
What Stem Cell Therapy Actually Is
The Basic Mechanism: Cells That Signal Repair
The popular image of stem cell therapy, that injected cells simply “become” new tissue, is an oversimplification that current research largely does not support for most clinical applications. What research suggests is happening is considerably more nuanced, and arguably more interesting.
Mesenchymal stem cells (MSCs), the cell type most commonly used in orthopedic and systemic regenerative applications, are understood primarily as powerful signaling agents. When introduced to an injury site or an inflamed tissue environment, MSCs release a range of bioactive molecules including growth factors, cytokines, and extracellular vesicles such as exosomes. This process is called paracrine signaling, and clinical evidence indicates it is the dominant mechanism behind MSC therapeutic effects rather than direct differentiation into new tissue cells.
The secretome of MSCs, meaning the totality of what they release into the surrounding environment, includes molecules such as vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-beta), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF). Each of these signals has downstream effects: promoting new blood vessel formation, modulating inflammation, recruiting the body’s own repair cells to the area, and supporting tissue remodeling.
Research published in frontline immunology journals also highlights MSC immunomodulatory effects. Studies suggest MSCs may inhibit T-cell proliferation, reduce pro-inflammatory macrophage (M1) activity, and encourage anti-inflammatory macrophage (M2) polarization through secretion of molecules including prostaglandin E2 (PGE2) and indoleamine 2,3-dioxygenase (IDO). In joints affected by osteoarthritis, this shift may contribute to a less destructive inflammatory environment.
A more recently identified mechanism involves what researchers call mitochondrial transfer. MSCs appear capable of donating mitochondria, the energy-producing structures within cells, to injured or dysfunctional cells nearby. Preclinical research has linked this mechanism to improved cellular energy production in conditions involving oxidative stress and tissue injury. The science here is still developing, and clinical translation is not yet fully established.
What this means practically is that “repair signaling” is a more accurate description of how MSC therapy works in most outpatient settings than “becoming new tissue.” The cells create a biological environment that may support the body’s own healing processes.
MSCs also carry a homing capacity. Research suggests that when introduced near an injury site or inflammation source, MSCs respond to chemical signals, called chemotactic gradients, and migrate toward areas of greatest need. This property contributes to the rationale for site-specific delivery using imaging guidance.
Where Stem Cells Come From in Medical Settings
Stem cells used in clinical settings are drawn from several primary sources, each with different characteristics and clinical applications.
Bone marrow is one of the most established sources. Bone marrow aspirate collected from the iliac crest of the pelvis contains a population of MSCs along with hematopoietic progenitor cells. The MSC population in bone marrow is relatively small as a percentage of total cells, which is why processing and concentration are important steps in preparing a therapeutic dose.
Adipose tissue, meaning fat tissue, is another well-studied source. The stromal vascular fraction (SVF) derived from adipose contains a higher concentration of MSCs per unit volume compared to bone marrow in many cases. Mini-lipoaspiration procedures can harvest adipose tissue with minimal patient discomfort, making this source accessible in outpatient settings. Research suggests adipose-derived MSCs share many functional properties with bone marrow-derived MSCs, though some researchers note differences in their growth factor profiles.
Umbilical cord tissue and Wharton’s jelly represent a third source category. These tissues, collected at birth with donor consent, contain MSCs that are generally regarded as more primitive and proliferative than those from adult sources. Because these are derived from a donor rather than the patient, they require different regulatory and safety considerations.
The physician’s choice of source typically reflects the clinical need, the patient’s individual biology, and the condition being treated.
The Main Types Used in Clinical Practice
Autologous Therapy (Your Own Cells)
Autologous stem cell therapy means the patient is both the donor and the recipient. Cells are collected from the patient’s own body, processed, and reintroduced during the same treatment plan. In the United States outpatient context, this is the most common approach for MSC-based regenerative procedures.
The primary clinical advantage of autologous therapy is that the immune system recognizes the cells as self. There is no requirement for HLA (human leukocyte antigen) matching, and the risk of immune rejection or graft-versus-host disease, which is a condition where transplanted cells attack the recipient’s tissues, is considered to be virtually eliminated. This safety profile makes autologous therapy well-suited for outpatient settings without the immunosuppression infrastructure of transplant centers.
From a regulatory standpoint, using a patient’s own minimally manipulated cells for homologous use falls under a distinct category in FDA guidance compared to allogeneic or heavily expanded cell products. Patients considering any stem cell procedure in the U.S. should ask their physician about the specific regulatory framework that applies to the cells they will receive.
Allogeneic Sources: Donor and Cord-Derived Cells
Allogeneic therapy uses cells from a donor. This category includes bone marrow donations from matched donors, cord blood, cord tissue, and Wharton’s jelly-derived MSCs. The appeal of allogeneic approaches is the potential for standardization and off-the-shelf availability. Donor-derived cells can theoretically be prepared in advance and administered without a harvesting appointment.
However, allogeneic approaches carry immunological considerations that autologous treatments do not. Even when MSCs are considered to have relatively low immunogenicity compared to other cell types, the risk of immune response is not fully eliminated. Donors must be screened for infectious diseases and other health factors. Regulatory requirements for allogeneic cell products are generally more extensive than for autologous minimally manipulated cells.
In December 2024, the FDA approved the first allogeneic MSC therapy for commercial use, a product called Ryoncil (remestemcel-L), for steroid-resistant acute graft-versus-host disease in pediatric patients. This approval applies to a specific clinical application and does not broadly characterize all allogeneic MSC uses.
Which Type Is Used and Why It Matters
The choice between autologous and allogeneic sources is a clinical decision that a physician makes based on multiple factors. These include the patient’s overall health status, the condition being treated, the patient’s age and cell quality considerations, available harvest sites, and the regulatory context of the specific procedure.
In many outpatient regenerative medicine settings, autologous therapy is the standard approach because it avoids immune complications, does not require donor matching, and uses the patient’s own biology as the foundation. The physician’s assessment of the patient’s ability to yield a sufficient, viable cell population from their own tissues is a central part of this evaluation.
What Stem Cell Therapy Is Used For
Orthopedic and Joint Applications
Musculoskeletal conditions represent the most established and most studied application area for MSC-based therapy in outpatient settings. Research has focused on osteoarthritis, cartilage degradation, tendon injuries, and ligament repair.
The biological rationale for joint applications is supported by what MSCs do at the paracrine level. In osteoarthritic joints, inflammation and protease activity progressively break down cartilage. Research suggests that MSCs introduced into the joint space may modulate this inflammatory environment and support local repair signaling. Intra-articular delivery guided by ultrasound or fluoroscopy allows the physician to place cells at the specific site of pathology.
Clinical evidence indicates varying degrees of benefit across patient populations, and outcomes are not uniform. Patients with early-to-moderate osteoarthritis appear to respond more consistently than those with advanced, bone-on-bone joint destruction, where the structural environment may be less conducive to repair signaling.
Tendon and ligament applications follow similar paracrine rationale. Research suggests that MSC-secreted growth factors including TGF-beta and PDGF may support tendon matrix remodeling and reduce chronic inflammation at injury sites.
Neurological Applications
Research into neurological applications of MSC therapy is ongoing and generally at earlier stages than orthopedic evidence. Applications under investigation include peripheral neuropathy, post-stroke recovery support, and neurodegenerative conditions.
MSCs secrete neurotrophic factors including NGF and BDNF, which are proteins involved in nerve cell survival and function. Some early clinical evidence suggests that patients with peripheral neuropathy may report symptom changes following MSC treatment, though study sizes are generally small and the mechanisms are not fully characterized.
It is important to note that the evidence base for neurological applications is still developing. Patients considering stem cell therapy for neurological conditions should have a detailed conversation with a physician about the current state of evidence and what realistic expectations look like.
Systemic and Organ-Related Conditions
Research has explored MSC applications in autoimmune conditions, organ function support, and metabolic diseases. The immunomodulatory properties of MSCs provide a theoretical basis for use in conditions where dysregulated immune activity contributes to tissue damage.
Many systemic applications remain investigational. The transition from promising preclinical results to proven clinical benefit has been slower in systemic conditions than in orthopedics. Honest candidacy assessment requires that a physician review the current evidence base for a specific condition before recommending a systemic regenerative approach.
Wellness and Preventive Use
Some patients seek stem cell therapy before significant degeneration has occurred, with the goal of optimizing cellular signaling environments or addressing subclinical decline. This framing of regenerative medicine as proactive rather than reactive is a growing area of patient interest.
The evidence base for preventive applications is limited relative to therapeutic applications. Patients considering this approach should understand that research in this area is less established, and the clinical rationale depends more heavily on theoretical frameworks than on outcomes data from controlled trials.
How This Differs from Conventional Medical Care
Symptom Management vs. Tissue-Level Support
Conventional medical care for conditions like osteoarthritis typically involves non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, hyaluronic acid injections, and physical therapy. Each of these works at the level of symptom management: reducing pain, decreasing inflammation, and improving function in ways that do not structurally address the underlying tissue.
NSAIDs reduce prostaglandin synthesis and therefore inflammatory signaling, but they do not address cartilage degradation. Corticosteroid injections suppress the local immune response and reduce inflammation for a period, but repeated use may accelerate cartilage breakdown over time. These approaches have important clinical value, particularly for managing pain and preserving function, but their mechanism of action is fundamentally different from what regenerative medicine attempts.
Regenerative approaches aim to work at the level of the biological repair mechanism itself, introducing signals that may support tissue remodeling and reduce the destructive environment in a joint. This is a structural difference in therapeutic goal, not a claim that regenerative medicine is superior in all cases or for all patients.
What Regenerative Medicine Does Not Replace
Clarity about scope matters. Regenerative medicine does not replace surgical intervention when anatomy requires it. A joint with complete structural failure, a torn ligament requiring reattachment, or a meniscus with a mechanical tear that alters joint mechanics may require surgery that no injection-based therapy can substitute for.
Regenerative medicine also does not replace acute emergency care, primary care diagnostics, or disease management medicine. It does not diagnose conditions, and it functions as a complement to, rather than a replacement for, a patient’s relationship with their primary care physician and specialists.
The honest positioning of regenerative medicine as one part of a broader clinical picture, appropriate for some patients and some conditions at specific stages of progression, is the foundation of responsible care. A physician-led approach means that every patient receives an individualized candidacy assessment before any procedure is recommended.
Sources
- Paracrine Mechanisms of Mesenchymal Stem Cell-Based Therapy: Current Status and Perspectives — PubMed
- Mesenchymal Stem/Stromal Cells and Their Paracrine Activity — Immunomodulation Mechanisms — PMC
- Cell Therapy: Types, Regulation, and Clinical Benefits — PMC
- Allogeneic vs. Autologous Mesenchymal Stem/Stromal Cells in Clinical Practice — PMC
- Mesenchymal Stem Cells in Osteoarthritis Therapy: A Review — PMC
- FDA Guidance: Minimal Manipulation and Homologous Use of HCT/Ps — FDA.gov
Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.